Physician profile
Sharon Juliana Yee
NPI 1215027560
$43,948.60
in general payments reported to CMS, 2019-2025
58 companies · $7,489 in 2025
The $7,489 reported for 2025 was more than what 99% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,771 · 2020: $1,918 · 2021: $4,596 · 2022: $5,618 · 2023: $8,285 · 2024: $8,272 · 2025: $7,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $11K · Education: $617 · Travel and Lodging: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,026.02 |
| Consulting Fee | $10,787.50 |
| Education | $617.10 |
| Travel and Lodging | $615.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,832.52 | 2019-2025 | Imbruvica, Darzalex, Erleada |
| Seagen INC. | $5,565.90 | 2019-2020 | |
| Incyte Corporation | $5,538.36 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Gilead Sciences, INC. | $4,070.28 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $2,999.60 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Geron Corporation | $2,874.69 | 2025 | Imetelstat |
| Cti Biopharma Corp. | $1,725.00 | 2022 | |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Exelixis INC. | $1,511.05 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $1,393.12 | 2019-2025 | |
| Pfizer INC. | $1,038.98 | 2019-2025 | |
| Astellas Pharma US INC | $1,038.07 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Genentech USA, INC. | $907.44 | 2019-2025 | Venclexta |
| Celgene Corporation | $738.44 | 2019-2025 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $681.21 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $552.91 | 2020-2025 | Xpovio |
| Glaxosmithkline, LLC. | $545.03 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Puma Biotechnology, INC. | $486.89 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $423.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $385.39 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $376.87 | 2019-2025 | Lupron Depot |
| Amgen INC. | $360.82 | 2019-2023 | Blincyto, Lumakras, Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $283.04 | 2019-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.33 | 2019-2025 | Gilotrif |
| Beone Medicines USA, INC. | $232.24 | 2025 | Brukinsa |
| Sobi, INC | $207.95 | 2023-2025 | |
| Myovant Sciences INC. | $159.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $159.03 | 2020-2023 | |
| Organon LLC | $157.75 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $156.15 | 2024-2025 | Pyrukynd |
| Eisai INC. | $144.42 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $143.84 | 2023-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $120.34 | 2023-2025 | Besremi |
| Emd Serono, INC. | $116.96 | 2024 | |
| Progenics Pharmaceuticals, INC. | $103.56 | 2022-2025 | Pylarify |
| Lilly USA, LLC | $94.12 | 2020-2025 | Jaypirca, Verzenio |
| Dendreon Pharmaceuticals LLC | $89.75 | 2025 | Provenge |
| Beigene USA, INC. | $86.34 | 2020-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $83.00 | 2023-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $77.38 | 2019-2024 | |
| Tesaro, INC. | $70.55 | 2019 | |
| Global Blood Therapeutics, INC. | $49.14 | 2021 | |
| Syndax Pharmaceuticals, INC. | $44.47 | 2025 | |
| Mirati Therapeutics, INC. | $44.06 | 2023-2024 | Krazati |
| Tolmar Pharmaceuticals, INC. | $42.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $40.51 | 2020 | |
| Alexion Pharmaceuticals, INC. | $24.96 | 2024 | Ultomiris |
| Lexicon Pharmaceuticals, INC. | $24.27 | 2019 | |
| Tersera Therapeutics LLC | $23.38 | 2021 | |
| Deciphera Pharmaceuticals INC. | $22.97 | 2025 | Qinlock, Romvimza |
| Morphosys, US INC. | $22.86 | 2021 | |
| Immunomedics, INC. | $21.82 | 2020 | |
| Caris Mpi, INC. | $21.28 | 2025 | Mi Cancer Seek |
| Alnylam Pharmaceuticals INC. | $17.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.46 | 2019 | |
| Verastem, INC. | $16.19 | 2019 | |
| Tolmar, INC. | $14.43 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $14.28 | 2023 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.